About Us

● Keymed has entered into a global exclusive license agreement 

with Astrazeneca for the development and commercialization 

of CMG901, and will receive an upfront payment of $63m 

on transaction, as well as aditional milestone payments of

 up to $1.1bn and tiered royalties up to low double digits; 

● The first subject has been dosed in Phase I clinical trial

of CM369 (CCR8), co-developed by Keymed & InnoCare